Cytarabine and daunorubicin liposomal (Vyxeos)
Mechanism of action
Disease for which it is used
History of changes in FDA indication
- 8/3/2017: Granted FDA regular approval "for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis."
Also known as
- Code name: CPX-351
- Brand name: Vyxeos